key: cord-0993896-smix4k6x
authors: Brown, Li-An K.; Freemantle, Nick; Breuer, Judy; Dehbi, Hakim-Moulay; Chowdhury, Kashfia; Jones, Gemma; Ikeji, Felicia; Ndoutoumou, Amalia; Santhirakumar, Krishneya; Longley, Nicky; Checkley, Anna M.; Standing, Joseph F.; Lowe, David M.
title: Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial
date: 2021-03-08
journal: Trials
DOI: 10.1186/s13063-021-05139-2
sha: ddf92ba9a992476c893081988c6a12624937399c
doc_id: 993896
cord_uid: smix4k6x

OBJECTIVES: The objective of this trial is to assess whether early antiviral therapy in outpatients with COVID-19 with either favipiravir plus lopinavir/ritonavir, lopinavir/ritonavir alone, or favipiravir alone, is associated with a decrease in viral load of SARS-CoV-2 compared with placebo. TRIAL DESIGN: FLARE is a phase IIA randomised, double-blind, 2x2 factorial placebo-controlled, interventional trial. PARTICIPANTS: This trial is being conducted in the United Kingdom, with Royal Free Hospital, London as the lead site. Participants are non-hospitalised adults with highly suspected COVID-19 within the first 5 days of symptom onset, or who have tested positive with SARS-CoV-2 causing COVID-19 within the first 7 days of symptom onset, or who are asymptomatic but tested positive for SARS-CoV-2 for the first time within the last 48 hours. Inclusion criteria are as follows: 1. Any adult with the following: Symptoms compatible with COVID-19 disease (Fever >37.8°C on at least one occasion AND either cough and/ or anosmia) within the first 5 days of symptom onset (date/time of enrolment must be within the first 5 days of symptom onset). OR ANY symptoms compatible with COVID-19 disease (may include, but are not limited to fever, cough, shortness of breath, malaise, myalgia, headache, coryza) and tested positive for SARS-CoV-2 within the first 7 days of symptom onset) (date/time of enrolment must be within the first 7 days of symptom onset). OR no symptoms but tested positive for SARS-CoV-2 within the last 48 hours (date/time of test must be within 48 hours of enrolment): 2. Male or female aged 18 years to 70 years old inclusive at screening; 3. Willing and able to take daily saliva samples; 4. Able to provide full informed consent and willing to comply with trial-related procedures. 1. Known hypersensitivity to any of the active ingredients or excipients in favipiravir and matched placebo, and in lopinavir/ritonavir and matched placebo (See Appendix 2). 2. Chronic liver disease at screening (known cirrhosis of any aetiology, chronic hepatitis (e.g. autoimmune, viral, steatohepatitis), cholangitis or any known elevation of liver aminotransferases with AST or ALT > 3 X ULN)*. 3. Chronic kidney disease (stage 3 or beyond) at screening: eGFR < 60 ml/min/1.73m(2) *. 4. HIV infection, if untreated, detectable viral load or on protease inhibitor therapy. 5. Any clinical condition which the investigator considers would make the participant unsuitable for the trial. 6. Concomitant medications known to interact with favipiravir and matched placebo, and with lopinavir/ritonavir and matched placebo, and carry risk of toxicity for the participant. 7. Current severe illness requiring hospitalisation. 8. Pregnancy and/ or breastfeeding. 9. Eligible female participants of childbearing potential and male participants with a partner of childbearing potential not willing to use highly effective contraceptive measures during the trial and within the time point specified following last trial treatment dose. 10. Participants enrolled in any other interventional drug or vaccine trial (co-enrolment in observational studies is acceptable). 11. Participants who have received the COVID-19 vaccine; *Considering the importance of early treatment of COVID-19 to impact viral load, the absence of known chronic liver/ kidney disease will be confirmed verbally by the participant during pre-screening and Screening/Baseline visit. Safety blood samples will be collected at Screening/Baseline visit (Day 1) and test results will be examined as soon as they become available and within 24 hours. INTERVENTION AND COMPARATOR: Arm 1: Favipiravir + Lopinavir/ritonavir. Arm 2: Favipiravir + Lopinavir/ritonavir placebo. Arm 3: Favipiravir placebo + Lopinavir/ritonavir. Arm 4: Favipiravir placebo + Lopinavir/ritonavir placebo. Oral favipiravir matched placebo at 1800mg twice daily on Day 1, followed by 400mg four (4) times daily from Day 2 to Day 7 PLUS lopinavir/ritonavir matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7. MAIN OUTCOMES: The primary outcome is upper respiratory tract viral load at Day 5. Percentage of participants with undetectable upper respiratory tract viral load after 5 days of therapy. Proportion of participants with undetectable stool viral load after 7 days of therapy. Rate of decrease in upper respiratory tract viral load during 7 days of therapy. Duration of fever following commencement of trial medications. Proportion of participants with hepatotoxicity after 7 days of therapy. Proportion of participants with other medication-related toxicity after 7 days of therapy and 14 days post-randomisation. Proportion of participants admitted to hospital with COVID-19 related illness. Proportion of participants admitted to ICU with COVID-19 related illness. Proportion of participants who have died with COVID-19 related illness. Pharmacokinetic and pharmacodynamic analysis of favipiravir. Exploratory: Proportion of participants with deleterious or resistance-conferring mutations in SARS-CoV-2. RANDOMISATION: Participants will be randomised 1:1:1:1 using a concealed online minimisation process, with the following factors: trial site, age (≤ 55 vs > 55 years old), gender, obesity (BMI <30 vs ≥30), symptomatic or asymptomatic, current smoking status (Yes = current smoker, No = ex-smoker, never smoker), ethnicity (Caucasian, other) and presence or absence of comorbidity (defined as diabetes, hypertension, ischaemic heart disease (including previous myocardial infarction), other heart disease (arrhythmia and valvular heart disease), asthma, COPD, other chronic respiratory disease). BLINDING (MASKING): Participants and investigators will both be blinded to treatment allocation (double-blind). NUMBERS TO BE RANDOMISED (SAMPLE SIZE): 240 participants, 60 in each arm. TRIAL STATUS: Protocol version 4.0 dated 7(th) January 2021. Date of first enrolment: October 2020. Recruitment is ongoing, with anticipated finish date of 31(st) March 2021. TRIAL REGISTRATION: The FLARE trial is registered with Clinicaltrials.gov, trial identifying number NCT04499677, date of registration 4(th) August 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05139-2.

This document was constructed using the Comprehensive Clinical Trials Unit (CCTU) at UCL Protocol template Version 5. It describes the FLARE trial, sponsored by UCL and co-ordinated by CCTU.

It provides information about procedures for entering participants into the trial, and provides sufficient detail to enable: an understanding of the background, rationale, objectives, trial population, intervention, methods, statistical analyses, ethical considerations, dissemination plans and administration of the trial; replication of key aspects of trial methods and conduct; and appraisal of the trial's scientific and ethical rigour from the time of ethics approval through to dissemination of the results. The protocol should not be used as an aide-memoire or guide for the treatment of other patients. Every care has been taken in drafting this protocol, but corrections or amendments may be necessary. These will be circulated to registered investigators in the trial. Sites entering participants for the first time should confirm they have the correct version through a member of the trial team at CCTU.

CCTU supports the commitment that its trials adhere to the SPIRIT guidelines. As such, the protocol template is based on an adaptation of the Medical Research Council CTU protocol template (2013) and the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Statement for protocols of clinical trials 1 . The SPIRIT Statement Explanation and Elaboration document 2 can be referred to, or a member of CCTU Protocol Review Committee can be contacted for further detail about specific items.

The trial will be conducted in compliance with the approved protocol, the Declaration of Helsinki . Agreements that include detailed roles and responsibilities will be in place between participating sites and CCTU.

Participating sites will inform CCTU as soon as they are aware of a possible serious breach of this protocol or GCP, so that CCTU can fulfil its requirement to report the breach if necessary within the timelines specified in the UK Clinical Trials Regulations (currently 7 days). For the purposes of this regulation a 'serious breach' is one that is likely to affect to a significant degree:

 The safety or physical or mental integrity of the subjects in the trial, or  The scientific value of the trial.

UCL is the trial sponsor and has delegated responsibility for the overall management of the FLARE trial to CCTU. Queries relating to UCL sponsorship of this trial should be addressed to the CCTU Director or via the Trial Team. 

These membership lists are correct at the time of writing; please see terms of reference documentation in the TMF for current lists. Type of fatty liver disease, characterised by inflammation of the liver with concurrent fat accumulation in liver Introduction

The 2020 pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency.

COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with first presentation of symptoms, followed by a later 'inflammatory' phase which results in severe disease in some individuals. It is known from other rapidly progressive infections such as sepsis and influenza that early treatment with antimicrobials is associated with better outcome. The hypothesis is that this holds for COVID-19 and that early antiviral treatment may prevent progression to the later phase of the disease.

The antiviral drug favipiravir is active against a broad range of viruses and has shown promising results in COVID-19 disease in two small Chinese studies 3 . The drug works similarly to remdesivir (another promising treatment for COVID-19), but unlike remdesivir (which is intravenous) it has a well-established and currently available oral formulation with a good safety profile. Furthermore, both Royal Free Hospital and Great Ormond Street Hospital (London) involved in this trial are amongst the only UK groups with direct clinical experience of this drug, having successfully used favipiravir to treat other viral infections.

The results of the early studies 3 on favipiravir in COVID-19 urgently need to be confirmed or refuted in a high-quality placebo-controlled trial. However, it should also be noted that single agent oral favipiravir may not be sufficient for rapid viral eradication.

Another antiviral with potential activity in COVID-19 is the combined tablet lopinavir/ritonavir (LPV/r). This is a well-established therapy for HIV infection and lopinavir is known to have some antiviral activity against coronaviruses. Although LPV/r did not demonstrate a significant impact in COVID-19 as a single therapy in a recent study 4 in severely unwell patients, a numerical reduction in mortality (8% versus 13%) and reduced intensive care stay was observed in patients who received the drug early. Favipiravir and LPV/r have different mechanisms of action so given together are likely to act at least additively, and possibly synergistically, providing strong rationale for a trial which examines combination therapy.

Therefore the plan is to conduct a proof-of-principle placebo-controlled clinical trial of favipiravir plus or minus LPV/r in adults. Participants with or without symptomatic COVID-19 or tested positive will be assigned to receive favipiravir plus LPV/r or favipiravir plus LPV/r placebo or favipiravir placebo plus LPV/r or favipiravir placebo plus LPV/r placebo. The primary outcome will be the difference in the amount of virus ('viral load') in the upper respiratory tract after 5 days of therapy. Secondary outcomes will include hospitalisation, major morbidity and mortality, pharmacokinetics, and impact of antiviral therapy on viral genetic mutation rate.

If favipiravir, LPV/r, or favipiravir with LPV/r demonstrate important antiviral effects without significant toxicity, there will be a strong case for a larger trial in people at high risk of hospitalisation or intensive care admission, for example older patients and/or those with comorbidities and with early disease.

In viral infections such as influenza, it is well recognised that early antiviral therapy is associated with improved clinical outcome. During the outbreak of Severe Acute Respiratory Syndrome Coronavirus-1 (SARS-CoV-1), treatment of patients with lopinavir/ritonavir (LPV/r) plus ribavirin initiated immediately upon diagnosis led to significant mortality decreases compared to historical controls 4 . Although a rather poor-quality study, this does provide an indication that early treatment may be beneficial. Another study on LPV/r plus ribavirin showed reduced mortality and need for intubation only when therapy was given early, with late rescue treatment having no effect 5 . Early postexposure prophylaxis against Middle East Respiratory Syndrome (MERS-CoV) in healthcare workers showed that LPV/r pus ribavirin reduced the incidence of infection from 28% to 0% 6 .

Two very recent pre-print papers 7,8 on the viral dynamics of SARS-CoV-2, the cause of COVID-19, provide simulations to show that viral load peaks around 3 days after symptom onset and that antiviral therapy started later than day 4 may have limited benefit. Furthermore, late antiviral therapy, once viral loads are high, risks selection for drug resistance. Therefore, there are strong grounds to believe that if antivirals are to have a place in the treatment of SARS-CoV-2, they should be given early and, if possible, within the first 7 days of symptom onset.

Viral load falls rapidly and hence placebo group participants may have negative viral loads by day 7 of treatment 9 (day 14 post symptom onset as subjects up to Day 7 post onset could be recruited in this trial). Therefore, Day 5 is the current best estimate of the time point at which drug-induced differences in viral loads are expected to be seen, and hence is the primary endpoint and time at which a formal assessment will be conducted. Given the uncertainty over viral trajectories in SARS-CoV-2 at present, daily viral loads will be taken and viral trajectory assessed as a secondary endpoint.

Both recent SARS-CoV-2 modelling papers suggest that, to be effective, drugs need to provide a minimum of 65% inhibition of viral replication, with this percentage increasing to 90% or more if therapy is initiated late. Based on the in vitro EC50s of re-purposed drugs currently being trialled such as hydroxychloroquine, lopinavir and interferon, percentage inhibition using monotherapies are expected to be 33%, 66% and 18% respectively, meaning monotherapy with the currently proposed re-purposed drugs may not be effective. Whilst caution needs to be exercised in extrapolating in vitro EC50 to clinical antiviral activity, combination therapy may improve the chances of achieving sufficient viral inhibition.

Using drugs with differing modes of action is a fundamental principle of antimicrobial chemotherapy and is used across the spectrum of infectious diseases (for example in HIV, tuberculosis, multi-drug resistant bacteria and invasive fungal disease). Furthermore, the most promising efficacy of antiviral therapy in SARS-CoV-1 and MERS-CoV was with two drugs with complimentary modes of action:

LPV/r plus ribavirin 4, 5, 6 . Therefore, there is strong reason to believe that combination therapy may be necessary, but the correct combination, with limited potential for iatrogenic harm and with a strong pharmacological rationale for their choice, must be selected.

Favipiravir Favipiravir, manufactured by Toyama Chemical Co. (part of Fujifilm, Japan) is a novel antiviral initially developed for influenza. The drug is metabolised to a ribosyl triphosphate form which specifically inhibits the RNA dependent RNA polymerase without affecting host RNA and DNA polymerases, thereby rendering it a specific inhibitor of viral RNA synthesis. A graphical representation of the mechanism of action, as provided by Fujifilm with specific reference to influenza, is provided in Figure 1 in Appendix 1. Favipiravir has been demonstrated to have a wide spectrum of activity against RNA viruses in vitro, as summarised in Figure 2 in Appendix 1. It has been used clinically in several viral infections and in some cases, the drug has been observed to induce viral mutagenesis 10 . Phase I studies and pharmacokinetic studies of favipiravir have indicated increased blood levels of uric acid and elevation of liver aminotransferases in some individuals ( Figure 4 in Appendix 1). Importantly, animal studies have indicated potential teratogenicity and the drug is distributed in sperm: therefore a negative pregnancy test for all women of child-bearing potential will be required and participants instructed to use adequate contraception for the duration of the treatment and 7 days afterwards.

Favipiravir has predominantly been used in clinical trials for influenza. Trials 3 for this indication include:

-A Phase I/II study in type A or B influenza using favipiravir doses 1800mg bd for 1 day followed by 800mg bd for 4 days (101 patients) or 2400mg/600mg/600mg for 1 day followed by 600mg tds for 4 days (82 patients) or placebo (88 patients).

-Two Phase III studies in type A or B influenza using favipiravir doses 1800mg bd for 1 day followed by 800mg bd for 4 days (301 and 526 patients respectively) or placebo (322 and 169 patients respectively).

-A global phase III study in type A or B influenza using favipiravir 1200mg/400mg for 1 day followed by 400mg bd for 4 days or oseltamivir 75mg bd for 5 days (377 and 380 patients respectively)

-A phase II study in type A or B influenza using favipiravir doses 1000mg bd for 1 day followed by 400mg bd for 4 days (88 patients) or 1200mg bd for 1 day followed by 800mg bd for 4 days (121 patients) or placebo (124 patients).

Safety data have been encouraging in these studies. Overall, the frequency of adverse events was 386/1472 (26.2%) with favipiravir versus 227/894 (25.4%) with placebo and there were no differences in the incidence of any specific adverse event between groups.

Favipiravir was also used for Ebola virus disease, especially in the JIKI trial in Guinea 11 . Doses (2400mg/2400mg/1200mg on Day 1 followed by 1200mg twice daily) were significantly higher than proposed for the current study. No drug related grade 3 or 4 clinical events were observed. In 41 of the 48 patients who survived, biochemical abnormalities of renal and liver function rapidly improved on treatment; 7 of 48 patients saw transient rises in one marker but all subsequently normalised despite continuing favipiravir. Biochemical abnormalities in patients who died were attributed to severe viral infection.

In London institutions such as Royal Free Hospital and Great Ormond Street Hospital (GOSH), favipiravir has been used as post-exposure prophylaxis for Ebola virus, for chronic norovirus infection, refractory influenza infection, astrovirus, respiratory syncytial virus and seasonal coronavirus. Occasional asymptomatic elevation of liver aminotransferase levels were observed, but no serious adverse events related to the drug. This includes in patients with immunodeficiencies who have received several months-worth of treatment.

Favipiravir is orally administered and well absorbed with close to 100% bioavailability 12 . Although higher doses have been used in Ebola, 1800 mg twice daily on day 1 followed by 800 mg twice daily is the highest dose to have been used in Phase II trials and for which safety is established, and hence is proposed in this trial. Whilst the dose in this protocol is higher than that proposed in most ongoing trials 13 , its safety has been established in previous studies and is lower than that used in Ebola. This dose should ensure plasma levels over 60 mcg/mL are achieved by the second dose and maintained in that range (Appendix 1, Figure 3 ) and the total daily dose will be split four times per day rather than twice per day (i.e. 400 mg four times per day vs 800 mg twice per day) with the aim of keeping trough levels as high as possible. Since participants will be recruited during the day, they will be asked to take both loading doses on the same day, separated by 6 hours (i.e. if the first 1800 mg dose is taken at 5pm, the next dose should be taken at 11pm). The importance of quickly achieving high antiviral levels outweighs the risk of potential toxicity and it should be noted Ebola dosing of 2400 mg separated by 8 hours has been previously used (see above).

Due to the possibility of nonlinear time dependent PK, an important secondary endpoint of this trial is to measure PK at Day 7. Assuming 60 mcg/ml can be achieved, this level is over 6-fold higher than the reported EC50 of favipiravir for SARS-CoV-2. However, since favipiravir is around 54% bound to plasma proteins, it still may only be predicted to yield 77% inhibition of viral replication.

Favipiravir has been used to treat patients with COVID-19 in two Chinese studies 14, 15 giving some indication about the likely clinical effect. The first study 14 was published but subsequently withdrawn for unspecified reasons. A new corrected version of this study has since been published. With this caveat, the authors had reported that favipiravir was administered (open-label) to 35 patients with COVID-19 and outcome was compared to 45 patients treated with lopinavir/ritonavir in the preceding week; all patients also received inhaled interferon and supportive care. The median time to viral clearance in the favipiravir-treated group was 4 days compared to 11 days in those who did not receive favipiravir (p<0.001). At Day 14 from the start of treatment, chest CT scans had improved in 91.4% of favipiravir-treated patients compared to 62.2% of those who did not receive favipiravir (p=0.004).

In the second study 15 , patients were consecutively recruited and randomly assigned to receive favipiravir or umifenovir (arbidol), a drug used for influenza in China; 120 participants were enrolled into each arm. In participants without severe disease, clinical recovery at 7 days was higher in the patients who received favipiravir (71.4% vs 55.9%, p=0.02). Time to resolution of fever and cough was also quicker in the favipiravir-treated group without severe illness. However, there was no significant difference in time to recovery among patients with severe disease, supporting the hypothesis that antiviral agents are best administered early in the disease course and certainly before the onset of respiratory failure.

LPV/r is a well-established, licensed protease inhibitor therapy in routine clinical usage for the treatment and prevention of HIV/AIDS. It combines lopinavir with a low dose of ritonavir. It is generally recommended for use in combination with other antiretrovirals. As such, it is difficult to discern side effects of an individual drug. Gastrointestinal complaints such as diarrhoea are the most common, reported by between 5% and 28% of patients depending on the study and concomitant antiretroviral medications. More serious side effects, including pancreatitis and disturbance of serum lipids, are reported but only appear to be a risk with longer term treatment.

The ritonavir component is a potent inhibitor of CYP450 liver enzymes (CYP3A4) and drug-drug interactions can be significant. Therefore, LPV/r should not be co-administered with medications that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life threatening events. Participants on any of these concomitant medications will be excluded from the trial. Participants with untreated or poorly controlled HIV infection will also be excluded, to prevent the risk of developing resistance, and those already receiving protease inhibitor therapy.

LPV/r has putative activity against SARS-CoV-2 16 and of the currently tested re-purposed therapies has the highest potential benefit based on in vitro data. Furthermore, unlike (hydroxy)chloroquine, LPV/r does not cause cardiac toxicity and does not risk harmful drug-drug interactions with favipiravir.

LPV/r has been trialled as monotherapy in a recent study 4 in severely unwell patients. There was no difference in time to clinical improvement or in 28-day mortality between treated and non-treated patients, but a numerical reduction in mortality was seen in those who initiated the medication less than 12 days from the onset of symptoms (8% versus 13%). Furthermore, reduced intensive care stay was observed in the treated group. In the absence of strong clinical pharmacology evidence to suggest otherwise, the proposal is to use the licensed adult dose of LPV/r (although the total daily dose will be divided into four times per day rather than twice per day).

Favipiravir and LPV/r have different mechanisms of action so given together are likely to act at least additively. There is a possibility that the combination is synergistic since for lopinavir and ribavirin (another drug acting on RNA polymerase) in vitro synergy has been demonstrated with SARS-CoV-1 4 .

The preliminary results seen for favipiravir urgently need to be confirmed (or refuted) in a well conducted, placebo-controlled trial. Therefore, there is a strong rationale for choosing to trial early oral antiviral therapy with favipiravir and to investigate its combination with LPV/r.

Antiviral medications are most likely to be effective when administered soon after infection. There is therefore an urgent need to study subjects who have recently developed symptoms, or have recently been tested positive with or without symptoms, and who can be sampled frequently to understand changes in viral load. This cohort will allow us to collect detailed trajectory data on early disease and understand how pharmacological interventions may affect this.

The objective of this trial is to assess whether early antiviral therapy with either favipiravir + LPV/r, LPV/r or favipiravir is associated with a decrease in viral load compared with placebo.

FLARE is a phase IIA randomised, double-blind, 2x2 factorial placebo-controlled, interventional trial.

Randomisation will be by minimisation, with the following factors: trial site, age (≤ 55 vs > 55 years old), gender, obesity (BMI <30 vs ≥30), symptomatic or asymptomatic, current smoking status (Yes = current smoker, No = ex-smoker, never smoker), ethnicity (Caucasian, other) and presence or absence of comorbidity (defined as diabetes, hypertension, ischaemic heart disease (including previous myocardial infarction), other heart disease (arrhythmia and valvular heart disease), asthma, COPD, other chronic respiratory disease).

Participants will be adults who have developed the early symptoms of COVID-19 within the first 5 days, or tested positive for SARS-CoV-2 within the first 7 days of symptom onset, or not presenting symptoms but tested positive within the last 48 hours (date/time of test must be within 48 hours of enrolment).

The trial sponsor has overall responsibility for site and investigator selection and has delegated this role to CCTU.

It is anticipated that the trial will take place at the Royal Free Hospital London (Royal Free London NHS Foundation Trust) -Lead site in the first instance.

Additional sites and participant identification centres (PIC) will be added if necessary.

Screening/Baseline trial assessments will be conducted on-site (in designated hospital area) or at participants' homes. Once participants have completed their self-isolation period, trial assessments will be conducted at sites (in a designated hospital area).

Once a site has been assessed as being suitable to participate in the trial, the trial team will provide them with a copy of this protocol and relevant trial documents.

To participate in the FLARE trial, Investigators and trial sites must fulfil a set of criteria that have been agreed by the FLARE Trial Management Group (TMG) and that are defined below.

Eligibility criteria:

 A named clinician is willing and appropriate to take Principal Investigator responsibility  Suitably trained staff are available to recruit participants, collect data and biospecimen samples  The site should be able to store, prepare and dispense IMP appropriately.

The investigator(s) must be willing to comply with the trial protocol (confirming their specific roles and responsibilities relating to the trial, and that their site is willing and able to comply with the requirements of the trial) as agreed in the site agreement. This includes confirmation of appropriate qualifications, by provision of a CV, familiarity with the appropriate use of any investigational products, agreement to comply with the principles of GCP, to permit monitoring and audit as necessary at the site, and to maintain documented evidence of all staff at the site who have been delegated significant trial related duties.

Resourcing at site The investigator(s) should be able to demonstrate a potential for recruiting the required number of suitable participants within the agreed recruitment period (i.e. the investigator(s) regularly treat(s) the target population). They should also have an adequate number of qualified staff and facilities available for the foreseen duration of the trial to enable them to conduct the trial properly and safely.

Sites will be expected to complete a delegation of responsibilities log and provide staff contact details.

Sites should have sufficient data management resources to allow prompt data return to CCTU.

On receipt of confirmation of capacity and capability, a signed site agreement, approved delegation of responsibilities log and staff contact details, the Trial Manager or delegate will notify the Principal Investigator (PI) in writing of the plans for site activation. Sites will not be permitted to recruit any participants until a letter for activation has been issued. The Trial Manager or delegate will be responsible for issuing this after a green light to recruit process has been completed.

The site must conduct the trial in compliance with the protocol as agreed by the Sponsor, by the MHRA and which was given favourable opinion by a Research Ethics Committee (REC) and the Health Research Authority (HRA). The PI or delegate must document and explain any deviation from the approved protocol, and communicate this to the trial team at the CCTU.

A list of activated sites may be obtained from the Trial Manager.

Any adults who have developed the early symptoms of COVID-19 within the first 5 days, or tested positive for SARS-CoV-2 within the first 7 days of symptom onset, or not presenting with symptoms but tested positive within the last 48 hours (date/time of test must be within 48 hours of enrolment). .

Recruitment will be done: 1) Via targeted advertising to the adult population 2) Via participant self-referral 3) Via employer referral (e.g. Occupational Health Services) 4) Via COVID-19 National Testing Programme 5) Via NHS registries and databases (e.g. NHS Digital)

There will be no exceptions (waivers) to eligibility requirements at the time of randomisation. Questions about eligibility criteria should be addressed prior to attempting to randomise the participant.

The eligibility criteria for this trial have been carefully considered and are the standards used to ensure that only medically appropriate participants are enrolled. Participants not meeting the criteria should not be enrolled into the trial for their safety and to ensure that the trial results can be appropriately used to make future treatment decisions for other people with similar disease or conditions. It is therefore vital that exceptions are not made to these eligibility criteria.

Participants will be considered eligible for enrolment in this trial if they fulfil all the inclusion criteria and none of the exclusion criteria as defined below.

Inclusion criteria are as follows:

1. Any adultwith the following:

o Symptoms compatible with COVID-19 disease (Fever >37.8 o C on at least one occasion AND either cough and/ or anosmia) within the first 5 days of symptom onset (date/time of enrolment must be within the first 5 days of symptom onset)

o OR ANY symptoms compatible with COVID-19 disease (may include, but are not limited to fever, cough, shortness of breath, malaise, myalgia, headache, coryza) and tested positive for SARS-CoV-2 within the first 7 days of symptom onset (date/time of enrolment must be within the first 7 days of symptom onset)

o OR no symptoms but tested positive for SARS-CoV-2 within the last 48 hours (date/time of test must be within 48 hours of enrolment)

2. Male or female aged 18 years to 70 years old inclusive at screening 3. Willing and able to take daily saliva samples 4. Able to provide full informed consent and willing to comply with trial-related procedures

Exclusion criteria are as follows:

1. Known hypersensitivity to any of the active ingredients or excipients in favipiravir and matched placebo, and in lopinavir/ritonavir and matched placebo (See Appendix 2) 2. Chronic liver disease at screening (known cirrhosis of any aetiology, chronic hepatitis (e.g.

autoimmune, viral, steatohepatitis), cholangitis or any known elevation of liver aminotransferases with AST or ALT > 3 X ULN)* 3. Chronic kidney disease (stage 3 or beyond) at screening: eGFR < 60 ml/min/1.73m 2 * 4. HIV infection, if untreated, detectable viral load or on protease inhibitor therapy 5. Any clinical condition which the investigator considers would make the participant unsuitable for the trial 6. Concomitant medications known to interact with favipiravir and matched placebo, and with lopinavir/ritonavir and matched placebo, and carry risk of toxicity for the participant (See Appendix 3) 7. Current severe illness requiring hospitalisation 8. Pregnancy and/ or breastfeeding 9. Eligible female participants of childbearing potential and male participants with a partner of childbearing potential not willing to use highly effective contraceptive measures during the trial and within the time point specified following last trial treatment dose. 10. Participants enrolled in any other interventional drug or vaccine trial (co-enrolment in observational studies is acceptable). 11. Participants who have received the COVID-19 vaccine.

* Considering the importance of early treatment of COVID-19 to impact viral load, the absence of chronic liver/ kidney disease will be confirmed verbally by the participant during prescreening and Screening/Baseline visit. Safety blood samples will be collected at Screening/Baseline visit (Day 1) and test results will be examined as soon as they become available within 24 hours.

Female participants of childbearing potential must not become pregnant and must use contraceptive methods with a failure rate of < 1% (highly effective contraceptive methods), supplemented with a barrier method (preferably male condom):

o during therapy o and for up to 7 days after stopping the therapy, unless abstinence is the chosen method of contraception. Abstinence is acceptable only as total abstinence from intercourse with male partners: when this is in line with the preferred and usual lifestyle of the participant.

WOCBP excludes women who are postmenopausal or permanently sterilised, e.g. tubal ligation, hysterectomy, bilateral salpingectomy or bilateral oophorectomy.

WOCBP participants should agree to remain consistent and to correctly use highly effective contraceptive methods that result in a failure rate of < 1% per year, supplemented with a barrier method (preferably male condom) during their participation in the trial. Contraception methods with low user dependency should preferably be used 17 .

This must be clearly documented in the CRF prior to their randomisation.

Highly effective contraceptive methods include:

o  Intrauterine device (IUD) -(low user dependency)  Intrauterine hormone-releasing system (IUS) -(low user dependency)  Bilateral tubal occlusion -(low user dependency)  Male partner sterilisation (vasectomy with documentation of azoospermia) prior to the female participants' entry into the study, and this male is the sole partner for that participant (low user dependency)

 Total sexual abstinence Periodic abstinence (for example, calendar, ovulation, sympto-thermal and post ovulation methods) and the withdrawal method are not considered acceptable methods of contraception.

Screening/Baseline visit: Following written consent, women of childbearing potential will undergo a urine pregnancy test prior to randomisation at Screening/Baseline visit (Day 1). The results of this pregnancy test must be available prior to dispensing the IMPs and should be clearly documented on the CRF.

After last day of treatment: a urine pregnancy test must be obtained for WOCBP at least 7 days after their last dose of IMPs (last day of treatment).

Due to probable teratogenicity of favipiravir, sexually active male participants should be required to use a condom as precautionary measure and advised that their female partners of child bearing potential use highly effective contraception methods during treatment and for at least 7 days after cessation of IMPs.

Investigators should inform all male participants of reproductive potential, including those planning to have children, of the potential risks and document this in the CRF.

Registered research nurse or research assistant, any other delegated individual or doctor trained in the FLARE trial protocol, GCP and use of appropriate PPE as per Public Health England Guidance (See Appendix 5). Research staff attending the participant's home must wear appropriate PPE in advance of entering the house, during the visits and until after they leave the premises. As in all situations during the pandemic, guidance on infection control should be followed, including handwashing. As a minimum, single use disposable plastic aprons, surgical mask and gloves must be worn at all times.

Home-visiting research staff should ensure that 'home visit' bags contain necessary additional PPE and clinical waste bags. All equipment used at visits should then be appropriately decontaminated when returning to the practice.

Each member of the Trial Team at each site will have their roles within the trial, as delegated by the PI and documented in the FLARE trial site delegation log. The FLARE trial team at UCL CCTU will collect CVs and current GCP training certificates for all staff working on the trial to document their qualifications and relevant experience. Protocol-specific training will be provided to participating sites prior to site activation. New site staff who start working on the trial after site activation occurs, will be provided with protocol specific training prior to performing trial related procedures.

The FLARE trial team at sites will be responsible for ascertaining whether the patient is currently taking part in a clinical trial. Participants may be enrolled in other observational studies but not in interventional drugs or vaccine trials.

Potential participants will be identified from several sources; as it is essential that participants are treated as soon as possible. Potential participants will be provided with trial information and a full participant information sheet (PIS) by email. When a participant has had time to review the PIS a telephone screening will be undertaken. This will allow rapid, efficient selection of participants most likely to pass the Screening/Baseline visit, and represents the best available strategy for practical screening in this trial. The telephone conversation will be conducted by delegated research staff. Participants will give verbal consent to disclose basic medical information to check for contraindications to treatment (e.g. Chronic liver and kidney disease, concomitant medications known to interact with trial medications) and to check provisional eligibility.

The following data collected during the pre-screening telephone contact: study site, age (≤ 55 vs > 55 years old), gender, obesity (BMI <30 vs ≥30), symptomatic or asymptomatic, current smoking status (Yes = current smoker, No = ex-smoker, never smoker), ethnicity (Caucasian, other) and presence or absence of comorbidity (defined as diabetes, hypertension, ischaemic heart disease (including previous myocardial infarction), other heart disease (arrhythmia and valvular heart disease), asthma, COPD, other chronic respiratory disease, will be used for the purposes of registration and IMP kit pre-allocation. Considering the importance of starting therapy immediately upon entering this trial, IMP kit codes will be pre-allocated to the participants ahead of the Screening/Baseline visit on Day 1, when they will be fully consented before randomisation can be completed. No IMP kit will be given to the participants until their eligibility has been confirmed. Participants will be considered fully randomised when they ingest their first dose of IMP.

If they decide to participate, an on-site (in designated hospital area) or a home Screening/Baseline visit will be arranged where participants will be able to ask any further questions about the trial and full informed consent will be taken after eligibility by all the criteria confirmed.

Where a participant requests to speak with a physician from the trial team the consent process will not be completed until the participant had spoken to the physician and had all their questions answered to their satisfaction.

Written informed consent to enter and be randomised into the trial must be obtained from participants, after explanation of the aims, methods, benefits and potential hazards of the trial and before any trial-specific procedures are performed or any samples are taken for the trial. If the delegated site staff taking informed consent is not a medically qualified investigator, they will have a conversation (via teleconference) with the site principal investigator or delegate while they are still at the participant's home: the principal investigator or delegate will confirm eligibility and consent, and approve each participant's enrolment. The conversation, name of the principal investigator or delegate and actions taken will be documented on the Screening/Baseline CRF. Where Screening/Baseline visit is taking place at site (in designated hospital area), delegated site staff taking informed consent will follow the same procedure described above and eligibility and consent will be confirmed by the site principal investigator or delegate in clinic.

The only procedures that may be performed in advance of written informed consent being obtained is the collection of data during the pre-screening telephone contact when participant's personal contact details (including home address) and verbal confirmation of interest will be obtained and documented, and IMP kit pre-allocation. Trial staff will record all telephone conversations in the source documents.

Delegated site staff will visit participants at their home or on-site (in a designated hospital area). After they have been given sufficient time to ask questions and provided written consent, participants will undergo final assessment for eligibility (including a urine pregnancy test for women of childbearing potential), and will be recruited to the trial. A baseline saliva sample for virological analysis and baseline blood samples will be taken. A baseline diagnostic nose and throat swab will be taken if the participant hasn't been tested for COVID-19 yet.

If they are eligible, participants will be randomised and provided with a trial medication kit, symptoms diary, containers for daily saliva samples collection, one stool collection container, a thermometer and instructions for taking their medications, collecting samples and recording daily body temperature readings.

Participants will be considered fully randomised once they take their first trial medication dose, witnessed by the delegated site staff and they meet all inclusion criteria following results from safety bloods collected at Screening/Baseline visit. Arrangements will be made for their next trial visits.

If participants are deemed ineligible following one of the above assessments, data will not be collected for these participants. .

The reason(s) for ineligibility will be explained to participants and any questions they have will be answered. They will be thanked for their participation and any relevant information from this will be recorded on the CRF.

If participants are deemed ineligible following results from safety bloods collected at Screening/Baseline visit, a delegated site research staff will contact the participant (within 6 hours of results receipt) to explain the reason(s) for ineligibility and instruct them to interrupt the therapy immediately. The research staff will enquire on any adverse reactions and side effects that the participant might have experienced since starting the trial medications and record details on the Screening/Baseline CRF. In order to ensure participant's safety, arrangements for immediate collection of the medication kit from the participant's home will be made (within 24 hours), and a pills count will be performed on receipt of the medication kit at site.

The interventions for this trial are favipiravir plus LPV/r or favipiravir plus LPV/r matched placebo or favipiravir matched placebo plus LPV/r or matched placebo of both drugs for 7 days.

RenaClinical Limited will be packaging, labelling, blinding and QP release all the medications for use in this trial. The trial medication will be delivered to Pharmacy, who will be responsible for local storage, dispensing, accountability and return of trial drugs.

RenaClinical Limited will be sourcing active Lopinavir/ritonavir, manufacturing Lopinavir/ritonavir matched placebo.

RenaClinical Limited will be also performing packaging, labelling, blinding and QP release of favipiravir tablets and matched placebo received from FUJIFILM Toyama Chemical Co., Ltd.

The trial medications will be packaged for clinical trial use in kits containing the adequate number of units required for the treatment period (7 days) and labelled in compliance with Annex 13 of GMP.

Each kit will contain: The treatment, packaging and labelling will be identical in appearance and treatment will be allocated using blinded kit codes (see 6.9.1.3).

Favipiravir (Avigan®) 200 mg tablets and matched placebo will be provided by FUJIFILM Toyama Chemical Co., Ltd.

On Day 1, 9 tablets (1800 mg) will be taken twice separated by at least 6 hours (e.g. if first dose is at 5pm the second dose should be at 11pm), followed by 2 tablets (400 mg) four (4) times daily from Day 2 to Day 7.

Lopinavir/ritonavir 200 mg/50 mg tablets will be sourced by RenaClinical Limited and matched placebo manufactured by the same company.

On Day 1, 2 tablets (400 mg/100 mg) will be taken twice separated by at least 6 hours (e.g. if first dose is at 5pm the second dose should be at 11pm), followed by 1 tablet (200mg/50mg) four (4) times daily from Day 2 to Day 7.

Detailed information with regard to the labelling, administration, storage etc. will be provided in the FLARE IMP Management Plan.

Treatment dosing regimen is summarised in Table 1 

Following randomisation at Screening/Baseline (Day 1), participants will take trial medications for 7 days. During this period, they will collect a daily saliva sample and complete a symptoms diary including four daily temperature measurements (except for Day 1 where only two temperature measurements will be recorded, and Day 7 where one or two temperature measurements will be recorded depending of the schedule time of Day 7 visit). The last dose will be taken at Day 7 (4 th dose on Day 7).

At Day 5, participants will receive a telephone call from the research team to ensure that participants collect their daily saliva sample, arrange time for Day 7 visit (PK sampling), to provide instructions for dose intake on Day 7and to enquire about any relevant clinical events (AEs and SAEs) that may require further clinical assessment.

In order to accommodate sites where the research staff do not work during weekends and where a participant is randomised on a Tuesday or a Wednesday, the Day 5 telephone call may be performed on the Friday of that week.

At Day 7, participants will be assessed by the trial team, undergo blood tests for toxicity and pharmacokinetic assessment and provide a stool sample.

In order to accommodate sites where the research staff do not work during weekends and where a participant is randomised on a Monday, a trial visit allowance of + 1 day will be permitted. Pharmacokinetics samples will not be collected for these participants as the last dose of IMP will be taken at Day 7 (4 th dose on Day 7).

Where no significantly abnormal results for safety blood tests taken at Day 7 are observed, participants will not undergo blood tests at the Day 14 visit. The research team will enquire about any relevant clinical events (AEs and SAEs) that may require further clinical assessment. Female participants of childbearing potential will attend the Day 14 visit in order to undergo urine pregnancy testing.

A trial visit allowance of +3 days will be permitted for the Day 14 visit.

Participants will have a telephone follow up three (3) weeks after their last day of treatment (Day 7). The research team will enquire about any relevant clinical events that may require further clinical assessment and collect further information through a questionnaire. A trial visit allowance of +/-3 days will be permitted for the Day 28 call.

Please refer to section 6.7 -Participant Timeline for details of the trial assessments performed at each visit.

No dose modifications will be permitted, there will be no planned interruptions to IMP administration. If participants suffer intolerable side effects or severe intercurrent illness, medication can be discontinued and the study team informed at the earliest opportunity.

As favipiravir and lopinavir/ritonavir are not licensed for treating COVID-19, their use in this trial will be off-label. Prescribing must only be conducted by members of the research team who have been delegated this task (prescribers) and appear on the Trial Delegation Log and have suitable training, qualifications and experience.

Only one dispensing episode will occur at Screening/Baseline Visit (Day 1) on receipt of a completed Trial Prescription, and participants will be provided with comprehensive instructions on the dosing regimen.

The IMP kits will be collected from pharmacy by the research staff on behalf of the participants ahead of the visit. The IMP kits will be placed in an insulated envelope with a single use temperature logger at the moment of collection from Pharmacy, and a first temperature reading recorded by the research staff. A second reading will be recorded once the research staff arrives at the participant's home. A chain of custody form will be completed by the research staff collecting the IMP and signed by both pharmacy and the research staff. The Chain of Custody form should be completed only if the participant has their Screening/Baseline visit at home.

For Screening/Baseline visits taking place on-site (in designated hospital area), the IMP kits will be collected from pharmacy by the research staff on behalf of the participants ahead of the visit, and dispensed directly to the participants during their visit.

Detailed information with regard to the labelling, administration and storage will be provided in the FLARE IMP Management Plan.

The site pharmacist will be delegated oversight of IMP supplies. Full IMP Accountability records will be maintained at the site pharmacy. Empty bottles and unused medication will be requested to be returned upon discontinuation of trial medication and destroyed or disposed of by the pharmacy on confirmation by the Sponsor. The CCTU will request copies of accountability logs and confirmation of destruction/disposal. Further details may be found in the FLARE IMP Management Plan.

For sites where empty bottles and participant's unused medication cannot be destroyed or disposed by pharmacy as part of the site local policy for COVID-19 trials, the research team will be responsible for the disposal of the IMP and for maintaining records of the IMP accountability. The CCTU will request copies of Participant Returns Accountability and Disposal Log to ensure IMP chain of custody.

All medications (except those that are contraindicated according to the Lopinavir/ritonavir SPC and Favipiravir IB or mentioned in Appendix 3) which the trial investigator responsible for the participant's care feels are clinically appropriate, are permitted in the trial.

Medications which are not permitted in the trial or which should be used with care are listed in Appendix 3.

If a participant is hospitalised during the trial period they will be encouraged where possible to continue taking trial medication, taking saliva samples, and recording temperature, but any urgent medical treatment required will be permitted.

If a participant reports overdose of trial medication they will be advised to seek medical help. Since only 7 days of supplies are provided and both drugs have reasonably wide therapeutic indices the consequence of overdose are thought to be limited.

In consenting to the trial, participants are consenting to trial treatments, trial follow-up and data collection. However, an individual participant may stop treatment early or be stopped early for any of the following reasons:  Unacceptable treatment toxicity or adverse event  Inter-current illness that prevents further treatment  Any change in the participant's condition that in the clinician's opinion justifies the discontinuation of treatment  Participant no longer wants to continue taking the trial medications  Withdrawing from the trial by the participant As participation in the trial is entirely voluntary, the participant may choose to discontinue trial treatment at any time without penalty or loss of benefits to which they would otherwise be entitled.

Although not obliged to give a reason for discontinuing their trial treatment, a reasonable effort should be made to establish this reason, whilst remaining fully respectful of the participant's rights.

Participants who discontinue protocol treatment, for any of the above reasons, should remain in the trial and undergo their remaining visits for the purpose of follow up and data analysis. 2 As Participants randomised on Mondays will not be able to attend their Day 7 visit on Sundays, PK samples will not be collected for these participants.

Sample timing: Samples will be drawn for pharmacokinetics on Day 7. Participants will be telephoned on Day 5 by the trial site team to arrange the Day 7 visit time.

If Day 7 visit scheduled for the morning (before 12:00): Participants will be instructed to take the morning dose and record the time to the nearest minute of that dose. The second dose of the day should not be taken until after the study visit. A blood sample will be drawn for PK sampling during the visit, and time to the nearest minute recorded. The second dose of the day will then be taken and the time to the nearest minute recorded. A further blood sample will be drawn after 30 to 60 minutes with time to the nearest minute recorded If Day 7 visit scheduled for the afternoon (after 12:00): Participants will be instructed to take the morning dose (first dose of the day) and the lunchtime dose (second dose of the day) which should be taken at 12:00. Participants will be asked to record the time to the nearest minute of the second dose of the day. A blood sample will be drawn for PK sampling during the visit, and time to the nearest minute recorded. The afternoon dose (third dose of the day) will then be taken and the time to the nearest minute recorded. A further blood sample will be drawn after 30 to 60 minutes with time to the nearest minute recorded Sample collection: If sampling from a newly inserted venous cannula, 2 mL of blood should be drawn and discarded. Then 2mL of blood should be collected into a plasma sampling tube, with time to the nearest minute and date recorded along with the participant ID. The next scheduled dose should then immediately be taken with time to the nearest minute recorded. A further 2mL of blood should be collected into a plasma sampling tube, with time to the nearest minute and date recorded along with the participant ID 30 to 60 minutes later.

 Safety bloods (Full blood count, urea and electrolytes, liver function tests and uric acid)sent to Great Ormond Street Hospital NHS diagnostic laboratory for standard assays, or will be analysed locally where applicable and as agreed with the Sponsor prior to site activation.

 Serum for storage -sent to Royal Free Hospital Centre for Clinical Microbiology (CCM) and processed by the laboratory staff: sample centrifuged and supernatant stored at -80 o C  Diagnostic nasopharyngeal swab -sent to Great Ormond Street Hospital NHS diagnostic laboratory for standard PCR assay for SARS-CoV-2, or will be analysed locally where applicable and as agreed with the Sponsor prior to site activation. Detailed information with regard to the samples collection, labelling, storage and processing will be provided in the FLARE Samples Management Plan.

The primary outcome is the upper respiratory tract viral load at Day 5.

Method of measurement: quantitative polymerase chain reaction (PCR) performed on saliva samples.

The secondary outcomes are the following: 

If a participant chooses to discontinue their trial treatment, they should continue to be followed up as closely as possible to the follow-up schedule defined in the protocol, providing they are willing to. They should be encouraged and facilitated not to leave the whole trial, even though they no longer take the trial treatment. If, however, the participant exercises the view that they no longer wish to be followed up either, this view must be respected and the participant withdrawn entirely from the trial. CCTU should be informed of the withdrawal in writing using the appropriate FLARE trial documentation. Data already collected will be kept and included in analyses according to the intention-to-treat principle for all participants who stop follow up early.

Participants who stop trial follow-up early will not be replaced.

If a participant's baseline diagnostic swab for SARS-CoV-2 is negative, they will be retained in the trial due to the relatively high rate of false negative results in this test. However, if the baseline saliva PCR is also negative, they will be excluded from the modified ITT analysis (see protocol section 6.11.5 Analysis Population and Missing Data).

Participants who start Day 1 of dosing but are deemed ineligible following results from safety bloods collected at Screening/Baseline visit will be considered as screen failure.

If a participant moves from the area making continued follow up at their consenting centre inappropriate, every effort should be made for them to be visited or to return for at least one visit. Given the short duration of follow-up, this is not anticipated to be a significant issue.

All efforts will be made to ensure complete follow-up all of participants, including via a telephone call from the trial team on Day 5 to ensure collection of saliva samples for the primary end-point. Given the short duration of follow-up, loss to follow-up is not anticipated to be a significant issue. However, participants failing to attend their scheduled follow-up visits should be contacted as soon as possible to re-arrange their visits at a more suitable date. Participants will be considered as lost to follow-up after three unsuccessful attempts (3 consecutive days) to contact them by the Research staff at participating sites.

When the whole target sample is recruited, the last participant has completed the last follow-up and the database is locked for analysis.

We have conducted extensive power calculation and power simulation exercises for the proposed factorial design. In the proposed design 240 participants (216 evaluable participants, which implies a 10% allowance for attrition and other methodological challenges) will be recruited, so that half of participants receive each of the experimental treatments, one quarter receive both treatments, and one quarter receive neither (with double dummy placebos in place). Both active treatments (main effects) provide 90% power with alpha of 2.5% to find a difference of 0.9 log10 viral load. The interaction term is powered (with 80% power and nominal alpha of 5%) to find a difference, either added to or subtracted from the additive effect of each treatment, of 1.0 log10 viral load to be statistically significant.

The trial will be advertised at each site and participant identification centre, as well as public domain websites (such as Sponsor webpage, NIHR Be Part of Research) and sponsor specific social media platforms, and potential participants provided with the trial team's contact details. Occupational Health teams at each participating centre will be provided with the trial information which they can provide to potential participants who consult them. Potential participants will also be approach after research on databases (e.g. NHS Digital). 240 participants will be recruited in total (60 participants in each arm) over an overall period of 6 months.

Should recruitment targets be slower than anticipated other London NHS organisations will be approached to enrol participants, which will be done centrally by the trial team in any case. Recruitment will be monitored regularly to identify any barriers to recruitment. Reporting will be conducted on a regular basis over the trial set up and recruitment period to the Trial Management Group (TMG), trial oversight committees and the funder. Remedial action will be put in place as soon as any concerns have been raised.

Participants will be in regular contact by phone and text message during the trial duration.

Sequence generation Participants will be randomised 1:1:1:1 using a concealed online minimisation process, with the following factors: study site, age (≤ 55 vs > 55 years old), gender, obesity (BMI <30 vs ≥30), symptomatic or asymptomatic, current smoking status (Yes = current smoker, No = ex-smoker, never smoker), ethnicity (Caucasian, other) and presence or absence of comorbidity (defined as diabetes, hypertension, ischaemic heart disease (including previous myocardial infarction), other heart disease (arrhythmia and valvular heart disease), asthma, COPD, other chronic respiratory disease).The minimisation algorithm will incorporate a random element to maximise balance in the stratifying variables between the randomised groups. These data will be collected at the pre-screening telephone contact and will be used for the purposes of registration and IMP kit pre-allocation. Considering the importance of starting therapy immediately upon entering this trial, IMP kit codes will be pre-allocated to the participants ahead of the Screening/Baseline visit on Day 1.

The Trial Statistician at CCTU will generate a sequence of unique identifiers for every active/placebo IMP kit. A copy of the sequence will be held securely at CCTU.

The IMP kit codes will be provided to Sealed Envelope and the IMP final manufacturer (RenaClinical Limited) such that the trial team and participants remain blind to treatment allocation.

Randomisation Implementation Minimisation is a dynamic system that depends on previous participants enrolled in the trial.

Following the pre-screening telephone contact before Screening/Baseline visit, the clinical investigator or delegate will enter the participant's initials, gender, age, height, weight and other factors detailed in Section 6.10.1.1 and confirm participant eligibility on the SealedEnvelope.com secure online system and allocate the appropriate PIN to the patient.

Delegated staff at participating sites will be provided with a secure login to the SealedEnvelope.com website, according to their role in the trial. The randomisation result will be shown directly online as a unique IMP kit code, with an email confirmation sent to the user and to the CCTU trial team. The investigator will provide details of the allocated unique kit code assigned to the participant on the prescription. Delegated staff will collect the allocated IMP kit from pharmacy on behalf of the participant ahead of the Screening/Baseline visit.

Randomisation will be considered complete after the participant has signed the consent form, ingested their first dose of trial medication during Screening/Baseline visit and is deemed eligible following results from safety bloods collected at Screening/Baseline visit. Participants who withdraw consent before taking their first dose or those who start Day 1 of dosing but are deemed ineligible following results from safety bloods will be considered as screen failures.

Participants and investigators will both be blinded to treatment allocation (double blinded). All IMP will be packaged and labelled to maintain blinding, and blinded IMP kit codes will be used to identify the medication. IMP kit codes will be linked to the PIN allocated to the participant at randomisation.

Detailed information regarding allocation implementation and blinding is provided in the IMP Management Plan and FLARE Randomisation and Unblinding Plan.

If the participant reports overdosing on study medication and is hospitalised as a result, emergency unblinding will take place.

All recruited participants will be given a card with contact details for the trial team including emergency contact 24 hours a day, 7 days per week. In the event of unblinding becoming necessary, emergency unblinding can occur at any time through the 24-hour web-based service offered by SealedEnvelope.com. Unblinding may occur for any participant experiencing a medical emergency for which the clinical management will be facilitated by the unblinding of the patient's treatment allocation. The Principal Investigator (PI) cannot overrule any decision made by a referring clinician. It is anticipated that in most instances, appropriate clinical management can proceed with the assumption that the patient has been treated with active IMP without needing to unblind the participant.

Detailed information regarding unblinding is provided in the Randomisation and Unblinding Plan.

All SAEs that are related to the trial medication (i.e. SARs) and are suspected to be unexpected i.e. SUSARs, need to be submitted to the regulatory agencies within pre-specified timelines. When SAEs reports are received at the CCTU, if the event is recorded as being a SUSAR then the following procedure will be used to unblind the SUSAR to determine if the participant was receiving active trial medication, and therefore, that the SUSAR needs onward reporting to the regulatory agencies:

A member of the CCTU trial SUSAR Reporting Team will unblind the participant's trial treatment allocation using the Sealed Envelope randomisation service.

If the participant is revealed to the CCTU SUSAR Reporting team to be receiving active treatment, the CCTU trial SUSAR Reporting Team member will report the SUSAR on the e-SUSAR database available through the MHRA website and to the MHRA and REC as required.

 This information will not be forwarded to the trial team at the CCTU or at the sites. It will be kept in a separate file by the CCTU SUSAR reporting team.

Each participant will be given a unique trial Participant Identification Number (PIN). Data will be collected at the time-points indicated in the Trial Schedule.

Data will be entered onto paper Case Record Forms (CRFs) prior to entry onto the database. Staff will receive training on data collection. Paper CRFs will be placed in clear plastic wallets which allow reading both sides of the CRF without opening the wallets. The plastic wallets will be decontaminated before leaving the participant's residence as per infection control guidance.

Data collection, data entry and queries raised by a member of the FLARE trial team will be conducted in line with the CCTU Standard Operating Procedures and the FLARE Data Management Plan.

Identification logs, screening and enrolment logs will be kept at the trial site in a locked cabinet within a secured room.

Research team members across all participating sites will receive training on the FLARE protocol and on the data entry in the approved FLARE database.

All data will be handled in accordance with the Data Protection Act 2018 and the GDPR 2016/679 including all further updates.

Data will be entered remotely in the approved FLARE database by delegated members of the research team at sites and protected using established CCTU procedures.

Coded data: Participants will be given a unique trial Participant Identification Number (PIN). Data will be entered under this identification number onto the central database stored on the servers based at CCTU. The database will be password protected and only accessible to members of the FLARE trial team at CCTU, and external regulators if requested. The servers are protected by firewalls and are patched and maintained according to best practice. The physical location of the servers is protected by CCTV and security door access.

The database and coding frames have been developed by the Clinical Trial Manager in conjunction with CCTU. The database software provides a number of features to help maintain data quality, including; maintaining an audit trail, allowing custom validations on all data, allowing users to raise data query requests, and search facilities to identify validation failure/ missing data.

After completion of the trial, the database will be retained on the servers of UCL for on-going analysis of secondary outcomes.

The identification, screening and enrolment logs, linking participant identifiable data to the pseudoanonymised PIN, will be held locally by the trial site. This will either be held in written form in a locked filing cabinet or electronically in password protected form on hospital computers. After completion of the trial the identification, screening and enrolment logs will be stored securely by the sites for 10 years unless otherwise advised by CCTU.

Every attempt to contact participants who do not adhere to the trial or who terminate participation prematurely will be made. This will include a telephone call on Day 5 from delegated members of the research team at sites. Participants will complete diaries and tablet counts at the end of the intervention period will be carried out. Reasons for non-adherence or non-retention will be documented.

If a participant wishes to withdraw consent (full withdrawal from treatment and follow-up), this should be documented on the withdrawal CRF. This conversation should be documented and the correct level of withdrawal selected on the CRF. Once consent has been withdrawn all follow-up will cease but all the information already obtained will be kept. To safeguard participant rights, only the minimum personally-identifiable information possible will be used. Due to the nature of the trial database and processes in place for auditing and accountability for trial data collection, it is not possible to remove all the data collected on the participant from the trial. Participants will be made aware of this at the time of recruitment.

A statistical analysis plan will be written and approved by the Trial Steering Committee and Independent Data Monitoring Committee prior to the first formal data analysis. The rest of this section provides the general statistical principles.

Statistical Methods -Outcomes A CONSORT diagram will be produced to report of the flow of participants in the trial.

Summary of baseline characteristics, by trial arms, will be by frequency and percentage for categorical variables, and for continuous variables by mean and standard deviation (or median and inter-quartile range for non-normally distributed data).

The primary endpoint will be analysed using an analysis of covariance (ANCOVA) model, including the main effects (each experimental treatment) as factors, the interaction between them and the baseline (Day 1) values of viral load.

Secondary endpoints include binary endpoints and continuous endpoints (note that the pharmacokinetic analysis of favipiravir is described in a separate section below).

For binary endpoints, a logistic regression will be used.

The comparison of duration of fever following commencement of medication between trial arms will be by t-test, or non-parametric equivalent depending on the distribution of the data.

Using an interaction term, we will explore whether a differential treatment effect is observed according to the following factors: sex (male vs female), age (≤ 55 vs > 55), obesity (BMI <30 vs ≥30), symptomatic or asymptomatic, current smoking status (Yes = current smoker, No = ex-smoker, never smoker), ethnicity (Caucasian, other) and presence or absence of comorbidity (defined as diabetes, hypertension, ischaemic heart disease (including previous myocardial infarction), other heart disease (arrhythmia and valvular heart disease), asthma, COPD, other chronic respiratory disease).

The primary outcome model will be adjusted for baseline viral load. The secondary outcome model of rate of decrease of viral load will also be adjusted for baseline viral load.

The primary analysis will be in the intention-to-treat (ITT) population. There will be no imputation for missing data for any of the study outcomes.

A modified ITT analysis will be performed that will only include participants who have a confirmed diagnosis at baseline of SARS-CoV-2 infection (diagnostic swab and saliva samples collected at Baseline).

On Day 7, a pre-dose and post-dose plasma samples will be taken for all participants in each arm. Participants will be asked to record the time to the nearest minute of each dose taken on Day 7.

Further details of sample processing are in section 6.5 Sample Management.

Population PKPD modelling and dosing simulations will be undertaken with non-linear mixed-effects modelling. Viral load with time will be modelled with a viral dynamic model, and the influence of favipiravir included to estimate an in vivo EC50.

Plasma concentrations will be sent from the bioanalytical laboratory on a spreadsheet, and dosing history and relevant covariate information extracted from the clinical database. These data will be imported into R (version 3.4 or above) and merged for exploratory analysis and formatted for subsequent modelling using NONMEM version 7.4 or above (Globomax, USA) and or nlmixr version 1.0 or above.

Model selection criteria will include: (i) successful minimisation, (ii) standard error of estimates, (iii) number of significant digits, (iv) termination of the covariance step and (v) correlation between model parameters. Goodness of fit will be assessed by graphical methods, including population and individual predicted vs. observed concentrations, conditional weighted residual vs. observed concentrations and time, correlation matrix for fixed vs. random effects, correlation matrix between parameters and covariates and normalised predictive distribution error (NPDE). Comparison of hierarchical models will be based on the likelihood ratio test. A superior model will be also expected to reduce inter-subject variance terms and/or residual error terms. Standard error of the parameter estimates will be approximated using of the asymptotic covariance matrix.

Viral sequencing will be undertaken according to established protocols and analysis of mutagenesis or the appearance of potentially deleterious mutations will be interrogated as previously described for other RNA viruses 10 .

An Independent Data Monitoring Committee (IDMC) will be appointed for the trial, the IDMC will review unblinded data and make recommendations to the Trial Steering Committee. Further details of the roles and responsibilities of the IDMC, including membership, relationships with other committees, decision making processes, and the timing and frequency of interim analyses, (and description of stopping rules and/or guidelines where applicable) are described in detail in the FLARE IDMC Terms of Reference (ToR).

There will be no interim analyses. Monitoring of the safety of the trial will be undertaken by the IDMC which will have untrammeled access to the trial data, and whose work is governed by a separate charter.

Descriptive statistics will be used to compare rates of adverse events between treatment arms. No additional formal monitoring will be performed except from those required by the IDMC.

Safety reporting Definitions of harm of the EU Directive 2001/20/EC Article 2 based on the principles of ICH GCP apply to this trial. 

Any untoward medical occurrence in a patient or clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this product.

Any untoward and unintended response to an investigational medicinal product related to any dose administered Unexpected Adverse Reaction (UAR)

An adverse reaction, the nature or severity of which is not consistent with the applicable product information (e.g. Investigator's Brochure for an unauthorised product or summary of product characteristics (SPC) for an authorised product)

Any AE or AR that at any dose:

 results in death  is life threatening*  requires hospitalisation or prolongs existing hospitalisation**  results in persistent or significant disability or incapacity  is a congenital anomaly or birth defect  or is another important medical condition***

A serious adverse reaction, the nature of severity of which is not consistent with the known potentially expected events associated with the applicable trial treatment. The event is evaluated as having a possible, probable or definite relationship to a trial treatment and is unexpected for that trial treatment. OR An unexpected adverse reaction is one that is not reported in the current and approved IB and SPCs section 4.8 or one that is more frequently reported or more severe than previously reported. If a SAR is assessed as being unexpected it becomes a SUSAR (Suspected, Unexpected, Serious Adverse Reaction).

* the term life threatening here refers to an event in which the patient (or participant) is at risk of death at the time of the event; it does not refer to an event that might hypothetically cause death if it was more severe (e.g. a silent myocardial infarction) ** Hospitalisation is defined as an in-patient admission, regardless of length of stay, even if the hospitalisation is a precautionary measure for continued observation. Hospitalisation for preexisting conditions (including elective procedures that have not worsened) do not constitute an SAE *** Medical judgement should be exercised in deciding whether an AE or AR is serious in other situations. Important AEs or ARs that may not be immediately life threatening or result in death or hospitalisation, but may seriously jeopardise the participant by requiring intervention to prevent one of the other outcomes listed in the table (e.g. a secondary malignancy, an allergic bronchospasm requiring intensive emergency treatment, seizures or blood dyscrasias that do not require hospitalisation, or development of drug dependency).

Due to the phototoxicity potential of favipiravir, participants should avoid excessive exposure to sunlight or artificial ultraviolet light.

Adverse reactions potentially related to favipiravir and lopinavir/ritonavir are listed in Appendix 4.

Adverse events (AEs) include:

 an exacerbation (i.e. increase in the frequency or intensity) of a pre-existing illness, episodic event or symptom (initially recorded at the screening/baseline visit), that is detected after trial drug administration/intervention  Occurrence of a new illness, episodic event or symptom, that is detected after trial drug administration/intervention  Any overdose of trial medication must be reported  Abnormalities shown on blood sample results which are considered in the opinion of the investigator as clinically significant against the local blood sample reference ranges.

Adverse events do NOT include:

 Medical or surgical procedures: the condition that leads to the procedure is the AE  Pre-existing disease or a condition present before treatment that does not worsen  Hospitalisation where no untoward or unintended response has occurred e.g. elective cosmetic surgery

Highly effective contraception, supplemented with a barrier method (preferably male condom), is required for this trial as favipiravir has potential teratogenic properties. Female participants with a positive pregnancy test at screening will not be eligible for inclusion in this trial. Participants will be advised to contact the trial team immediately if they, or the female partners of male participants, become pregnant during the treatment period or 7 days afterwards. Pregnant participants or partners will be advised to discontinue the trial medication immediately and to seek urgent medical advice.

All pregnancies and suspected pregnancies occurring in participants must be reported immediately to UCL CCTU upon site becoming aware using the Pregnancy Notification & Outcome Form CRF. A follow up Pregnancy report must be completed which will provide further information on pregnancy outcomes when this becomes available. Informed consent from the patient must be sought prior to collecting information on pregnancy outcomes. Any congenital abnormality or birth defect resulting from the pregnancy should be reported as an SAE to UCL CCTU.

Investigator responsibilities relating to safety reporting All non-serious AEs and ARs, whether expected or not, should be recorded in the participant Adverse Event Log and reported to CCTU within 14 days. SAEs and SARs should be notified to CCTU immediately the investigator becomes aware of the event (in no circumstance should this notification take longer than 24 hours).

Seriousness assessment When an AE or AR occurs, the investigator responsible for the care of the participant must first assess whether or not the event is serious using the definition given in Table 2 . If the event is classified as 'serious' then an SAE form must be completed and CCTU (or delegated body) notified immediately (no longer that 24hours). *Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money etc. ** Self-care AD refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications and not bedridden.

Causality The investigator must assess the causality of all serious events or reactions in relation to the trial therapy using the definitions in Table 3 . 

If an SAE is considered to be related to trial treatment, and treatment is discontinued, interrupted or the dose modified, refer to the relevant Interventions sections of the protocol.

If there is at least a possible involvement of the trial medications (including any comparators), the sponsor will assess the expectedness of the event. An unexpected adverse reaction is one that is not reported in the current Favipiravir IB and Lopinavir/ritonavir (LPV/r) SPC, or one that is more frequently reported or more severe than previously reported. The reference safety information (RSI) for this trial are the current version of the IB for Favipiravir (specifically section 7.13 'Reference Safety Information') and the SPC for Lopinavir/ritonavir (LPV/r) (specifically section 4.8 'Undesirable effects'). See the appended package inserts for a list of expected toxicities associated with the drugs being used in this trial. If a SAR is assessed as being unexpected it becomes a SUSAR (suspected, unexpected, serious adverse reaction). MHRA reporting guidelines apply (see protocol section 6.12.3.6 Notifications).

6.12.3.6.1 Notifications by the Investigator to CCTU CCTU must be notified of all SAEs within 24 hours of the investigator becoming aware of the event.

Investigators should notify CCTU of any SAEs and other Notifiable Adverse Events (NAEs) occurring from the time of randomisation until 30 days after the last protocol treatment administration, including SARs and SUSARs. From this point forward the site will not actively monitor SAEs or NAEs but will notify the CCTU of any SARs and SUSARs if they become aware of them until trial closure.

Any subsequent events that may be attributed to treatment should be reported to the MHRA using the yellow card system (https://yellowcard.mhra.gov.uk/the-yellow-card-scheme/).

The SAE form must be completed by the investigator (the consultant named on the delegation of responsibilities list who is responsible for the participant's care) with attention paid to the grading, and causality of the event. In the absence of the responsible investigator, the SAE form should be completed and signed by a member of the site trial team and emailed as appropriate within the timeline. The responsible investigator should check the SAE form at the earliest opportunity, make any changes necessary, sign and then email to CCTU. Detailed written reports should be completed as appropriate. Systems will be in place at the site to enable the investigator to check the form for clinical accuracy as soon as possible.

The minimum criteria required for reporting an SAE are the trial number and date of birth, name of reporting investigator and sufficient information on the event to confirm seriousness. Any further information regarding the event that is unavailable at the time of the first report should be sent as soon as it becomes available.

The SAE form must be scanned and sent by email to the trial team at CCTU on cctu.flare@ucl.ac.uk with the subject 'SAE FLARE'

Participants must be followed up until clinical recovery is complete and laboratory results have returned to normal or baseline values, or until the event has stabilised. Follow-up should continue after completion of protocol treatment and/or trial follow-up if necessary. Follow-up SAE forms (clearly marked as follow-up) should be completed and emailed to CCTU as further information becomes available. Additional information and/or copies of test results etc may be provided separately. The participant must be identified by trial number, date of birth and initials only. The participant's name should not be used on any correspondence and should be blacked out and replaced with trial identifiers on any test results.

6.12.3.6.2 CCTU responsibilities Medically qualified staff at CCTU and/or the Chief Investigator (CI or a medically qualified delegate) will review all SAE reports received. The sponsor clinical reviewer will complete the assessment of expectedness in light of the Reference Safety Information (RSI).

CCTU is undertaking the duties of trial sponsor and is responsible for the reporting of SUSARs and other SARs to the regulatory authorities (MHRA) and the ECs as appropriate. Fatal and life threatening SUSARs must be reported to the competent authorities within 7 days of CCTU becoming aware of the event; other SUSARs must be reported within 15 days.

CCTU will keep investigators informed of any safety issues that arise during the course of the trial.

The trial manager or delegate at CCTU will submit Development Safety Update Reports (DSURs) to competent authorities.

Definitions Quality Assurance (QA), defined as all the planned and systematic actions established to ensure the study is performed and data generated, documented and/or recorded and reported in compliance with the principles of ICH GCP and applicable regulatory requirements.

Quality Control (QC), defined as the operational techniques and activities performed within the Quality Management System (QMS) to verify that the requirements for quality of the trial related activities are fulfilled.

Quality and Risk Management Quality Assurance (QA) for the FLARE trial will implemented as described in CCTU Quality Management Policy and all SOPs and working instructions, which define the CCTU QMS that are applicable to the study's completion. The study proposal from the Chief Investigator is reviewed and developed in line with the processes required by the Trial Adoption Group (TAG) and this protocol has been reviewed, updated and finalised passing through the Protocol Review Committee process. The study will be subject to a dynamic risk assessment process throughout its life cycle; the CCTU Quality Management Group reviews the risk assessment periodically. Study risks are defined in terms of their impact on: the rights and safety of participants, project concept including study design, reliability of results and institutional risk; project management; and other considerations.

All aspects of the FLARE trial will be subject to the procedures followed by the CCTU QA function, this includes delivery of the CCTU Audit Programme and other due diligence procedures (vendor assessments). Aspects and entities that are subject to QA function procedures include, but are not limited to; outcome analysis laboratories, Contract Research Organisations CROs, study sites and internal CCTU procedures which apply to the FLARE trial.

Central Monitoring at CCTU CCTU staff will review Case Report Form (CRF) data for errors and missing key data points. The trial database will also be programmed to generate reports on errors and error rates. Essential trial issues, events and outputs, including defined key data points, will be detailed in the FLARE trial Data Management Plan and Quality Management and Monitoring Plan (QMMP).

On-site Monitoring The frequency, type and intensity of routine and triggered on-site monitoring will be detailed in the FLARE Quality Management and Monitoring Plan (QMMP). The QMMP will also detail the procedures for review and sign-off of monitoring reports. In the event of a request for a trial site inspection by any regulatory authority UCL CCTU must be notified as soon as possible.

Direct access to participant records Participating investigators must agree to allow trial related monitoring, including audits, REC review and regulatory inspections, by providing access to source data and other trial related documentation as required. Participant consent for this must be obtained as part of the informed consent process for the trial.

Trial Oversight Trial oversight is intended to preserve the integrity of the trial by independently verifying a variety of processes and prompting corrective action where necessary. The processes reviewed relate to participant enrolment, consent, eligibility, and allocation to trial groups; adherence to trial interventions and policies to protect participants, including reporting of harms; completeness, accuracy and timeliness of data collection; and will verify adherence to applicable policies detailed in the Compliance section of the protocol. Independent trial oversight complies with the CCTU trial oversight policy.

In multi-centre trials this oversight is considered and described both overall and for each recruiting centre by exploring the trial dataset or performing site visits as described in the FLARE QMMP.

Trial Team The Trial Team (TT) will be set up to assist with developing the design, co-ordination and day to day operational issues in the management of the trial, including budget management. The membership, frequency of meetings, activity (including trial conduct and data review) and authority will be covered in the TT terms of reference.

Trial Management Group A Trial Management Group (TMG) will be set up to assist with developing the design, co-ordination and strategic management of the trial. The membership, frequency of meetings, activity (including trial conduct and data review) and authority will be covered in the TMG terms of reference.

Independent Trial Steering Committee The Independent Trial Steering Committee (TSC) is the independent group responsible for oversight of the trial in order to safeguard the interests of trial participants. The TSC provides advice to the CI, CCTU, the funder and sponsor on all aspects of the trial through its independent Chair. The membership, frequency of meetings, activity (including trial conduct and data review) and authority will be covered in the TSC terms of reference.

Independent Data Monitoring Committee The Independent Data Monitoring Committee (IDMC) is the only oversight body that has access to unblinded accumulating comparative data. The IDMC is responsible for safeguarding the interests of trial participants, monitoring the accumulating data and making recommendations to the TSC on whether the trial should continue as planned. The membership, frequency of meetings, activity (including review of trial conduct and data) and authority will be covered in the IDMC terms of reference. The IDMC will advise the TSC through its Chair.

Trial Sponsor The role of the sponsor is to take on responsibility for securing the arrangements to initiate, manage and finance the trial. UCL is the trial sponsor and has delegated the duties as sponsor to CCTU via a signed letter of delegation.

Ethics and Dissemination

Before initiation of the trial at any clinical site, the protocol, all informed consent forms and any material to be given to the prospective participant will be submitted to the relevant EC for approval. Any subsequent amendments to these documents will be submitted for further approval. Before initiation of the trial at each additional clinical site, the same/amended documents will be submitted for local permissions.

The rights of the participant to refuse to participate in the trial without giving a reason must be respected. After the participant has entered the trial, the clinician remains free to give alternative treatment to that specified in the protocol, at any stage, if they assess this to be in the best interest of the participant. The reasons for doing so must be recorded. After randomisation the participant must remain within the trial for the purpose of follow up and data analysis according to the treatment option to which they have been allocated. However, the participant remains free to change their mind at any time about the protocol treatment and follow-up without giving a reason and without prejudicing their further treatment.

This protocol will be submitted to the MHRA.

This is a Clinical Trial of an Investigational Medicinal Product (IMP) as defined by the EU Directive 2001/20/EC. Therefore, a CTA is required in the UK.

The progress of the trial, safety issues and reports, including expedited reporting of SUSARs, will be reported to the Competent Authority, regulatory agency or equivalent in accordance with relevant national and local requirements and practices.

The protocol will be submitted by those delegated to do so to the Health Research Authority for national approval and relevant R&D departments of each participating site for review of local Trust Capacity and Capability. A copy of the local permissions (or other relevant approval as above) and of the Participant Information Sheet (PIS) and consent form on local headed paper must be forwarded to the co-ordinating centre before participants are randomised to the trial.

The protocol has received formal review and methodological, statistical, clinical and operational input from the CCTU Protocol Review Committee.

Protocol amendments will be agreed between the co-investigators and Trial Steering Committee. They will be submitted by the CI to the REC and MHRA and disseminated to the study team.

Participants will be provided with a Participant Information Sheet (PIS) and given time to read it fully. Following a discussion with a medical qualified investigator or suitable trained and authorised delegate, any questions will be satisfactorily answered and if the participant is willing to participate, written informed consent will be obtained. During the consent process it will be made completely and unambiguously clear that the participant is free to refuse to participate in all or any aspect of the trial, at any time and for any reason, without incurring any penalty or affecting their treatment.

Consent will be re-sought if new information becomes available that affects the participant's consent in any way. This will be documented in a revision to the participant information sheet and the participant will be asked to sign an updated consent form. These will be approved by the ethics committee prior to their use.

A copy of the approved consent form is available from the CCTU trial team.

Adequate measures will be in place to ensure all participant data collected are secure. Each participant will be assigned a unique trial Participant Identification Number (PIN). CRFs will record the participant initials and month/year of birth but not their name. The only link between the PIN and the participant's name will be on the screening log kept at site and accessed only by the site trial team.

Data will be recorded on the CRFs and entered onto the FLARE custom-designed database under this identification number. The database will be password protected and only accessible to members of the FLARE trial team at CCTU, trained and authorised site staff, and external regulators if requested. The servers are protected by firewalls and are patched and maintained according to best practice. The physical location of the servers is protected by CCTV and security door access.

Blood samples will be labelled with the FLARE participant identification number ensuring the pseudonymity of the participants who have provided the samples. At the laboratories (see section 6.5 Sample Management), brief clinical details will be stored including age and sex. Blood results will be stored on a web-based, secure confidential database, including after completion of the FLARE trial.

The investigators named on the protocol have no financial or other competing interests that impact on their responsibilities towards the scientific value or potential publishing activities associated with the trial.

UCL holds insurance to cover participants for injury caused by their participation in the FLARE trial. Participants may be able to claim compensation if they can prove that UCL has been negligent. However, as the FLARE trial is being carried out by hospital staff, the hospital continues to have a duty of care to the participant in the FLARE trial. UCL does not accept liability for any breach in the hospital's duty of care, or any negligence on the part of hospital employees. This applies whether the hospital is an NHS Trust or otherwise. This does not affect the participant's right to seek compensation via the non-negligence route.

Participants may also be able to claim compensation for injury caused by participation in the FLARE trial without the need to prove negligence on the part of UCL or another party. Participants who sustain injury and wish to make a claim for compensation should do so in writing in the first instance to the Chief Investigator, who will pass the claim to UCL's insurers, via the Sponsor's office.

Hospitals selected to participate in the FLARE trial shall provide clinical negligence insurance cover for harm caused by their employees and a copy of the relevant insurance policy or summary shall be provided to UCL, upon request.

FLARE is fully funded by LifeArc, grant reference [COVID0005]. It is not expected that any further external funding will be sought.

FUJIFILM Toyama Chemical Co., Ltd. will provide Favipiravir and matching placebo for the trial free of charge.

The investigators agree to archive and/or arrange for secure storage of FLARE trial materials and records for a minimum of 5 years after the close of the trial unless otherwise advised by the CCTU.

The CI, CPM, Trial Manager, Data Manager, Statistician and Trial Management Team will have full access to the trial data. Requests for access to trial data will be considered, and approved in writing where appropriate, after formal application to the TSC. Considerations for approving access are documented in the TSC Terms of Reference.

No arrangements will be in place for trial treatment after the planned treatment phase. Participants will be cared for as per standard NHS care should they require further treatment or hospitalisation for their COVID-19 symptoms. This will be made clear in the Participant Information Sheet.

The results of the trial will be published in peer-reviewed journals and may be presented at academic conferences. The results will be communicated to trial participants who have requested to be informed. Results will be reported within 6 months of the end of the trial. The results of the trial will be disseminated regardless of the direction of effect.

Publication and dissemination of the results will be coordinated by the FLARE trial team, following the CCTU Publication Policy.

All investigators and any other individual who has made a significant intellectual contribution (at the discretion of the Chief Investigator) will be authors. No professional writing assistance will be sought. Sildenafil Contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) only. Increased plasma concentrations of sildenafil. Thereby, increasing the potential for sildenafilassociated adverse events (which include hypotension and syncope).

Increased plasma concentrations of vardenafil.

Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral midazolam and triazolam. Thereby, increasing the risk of extreme sedation and respiratory depression from these agents.

Herbal products St. John's wort Herbal preparations containing St John's wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of lopinavir and ritonavir.

Strong CYP3A4 inhibitors such as protease inhibitors may increase bedaquiline exposure which could potentially increase the risk of bedaquiline-related adverse reactions. Therefore, combination of bedaquiline with lopinavir/ritonavir should be avoided. However, if the benefit outweighs the risk, co-administration of bedaquiline with lopinavir/ritonavir must be done with caution. More frequent electrocardiogram monitoring and monitoring of transaminases is recommended (refer to the bedaquiline SmPC).

Co-administration of delamanid with a strong inhibitor of CYP3A (as lopinavir/ritonavir) may increase exposure to delamanid metabolite, which has been associated with QTc prolongation. Therefore, if co-administration of delamanid with lopinavir/ritonavir is considered necessary, very frequent ECG monitoring throughout the full delamanid treatment period is recommended (refer to the delamanid SmPC).

Life-threatening and fatal drug interactions have been reported in patients treated with colchicine and strong inhibitors of CYP3A like ritonavir. Concomitant administration with colchicine is contraindicated in patients with renal and/or hepatic impairment.

The combination of Kaletra with:

-tadalafil, indicated for the treatment of pulmonary arterial hypertension, is not recommended;

-riociguat is not recommended;

-vorapaxar is not recommended;

-fusidic acid in osteo-articular infections is not recommended;

-salmeterol is not recommended;

-rivaroxaban is not recommended.

The combination of Kaletra with atorvastatin is not recommended. If the use of atorvastatin is considered strictly necessary, the lowest possible dose of atorvastatin should be administered with careful safety monitoring. Caution must also be exercised and reduced doses should be considered if Kaletra is used concurrently with rosuvastatin. If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.

Particular caution should be used when prescribing sildenafil or tadalafil for the treatment of erectile dysfunction in patients receiving Kaletra. Co-administration of Kaletra with these medicinal products is expected to substantially increase their concentrations and may result in associated adverse events such as hypotension, syncope, visual changes and prolonged erection. Concomitant use of avanafil or vardenafil and lopinavir/ritonavir is contraindicated. Concomitant use of sildenafil prescribed for the treatment of pulmonary arterial hypertension with Kaletra is contraindicated.

Particular caution must be used when prescribing Kaletra and medicinal products known to induce QT interval prolongation such as: chlorpheniramine, quinidine, erythromycin, clarithromycin. Indeed, Kaletra could increase concentrations of the co-administered medicinal products and this may result in an increase of their associated cardiac adverse reactions. Cardiac events have been reported with Kaletra in preclinical studies; therefore, the potential cardiac effects of Kaletra cannot be currently ruled out.

Co-administration of Kaletra with rifampicin is not recommended. Rifampicin in combination with Kaletra causes large decreases in lopinavir concentrations which may in turn significantly decrease the lopinavir therapeutic effect. Adequate exposure to lopinavir/ritonavir may be achieved when a higher dose of Kaletra is used but this is associated with a higher risk of liver and gastrointestinal toxicity. Therefore, this co-administration should be avoided unless judged strictly necessary.

Concomitant use of Kaletra and fluticasone or other glucocorticoids that are metabolised by CYP3A4, such as budesonide and triamcinolone, is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression.

To date, studies that have been completed include acetaminophen, hydrazine, norethindroneethinyl estradiol contraceptive (Ortho-Novum®), oseltamivir, pyrazinamine, and raloxifene. Except as noted, favipiravir co-administration was well tolerated and did not significantly alter the PK of either agent or in a clinically important manner.

Favipiravir in combination with paracetamol (acetaminophen) increased acetaminophen blood levels 14 to 17% based on plasma AUC comparisons.

Maximum permitted daily dose of paracetamol: 3000mg (max. 6 tablets in 24 hours).

Hydralazine: Co-administration of favipiravir and hydralazine resulted in a 13% reduction in hydralazine AUC. No changes in favipiravir PK were observed.

Ortho Novum® 1/35 (norethindrone and ethinyl estradiol): Favipiravir co-administration increased both norethindrone and ethinyl estradiol blood levels. Norethindrone plasma AUC increased 47% and ethinyl estradiol plasma AUC increased 43%. One subject discontinued the study due to transient, mildly elevated ALT (2.8 × normal) and AST (1.7 × normal).

Oseltamivir: Favipiravir did not alter the PK of oseltamivir nor did oseltamivir alter favipiravir PK.

Raloxifene: Co-administration of favipiravir with raloxifene, a potent aldehyde oxidase inhibitor, did not appreciably alter favipiravir PK. Favipiravir plasma AUC was reduced 15% when administered in combination with raloxifene.

Repaglinide: Favipiravir administration with repaglinide, an anti-diabetic agent that is extensively metabolized by CYP2C8 and CYP3A4, increased repaglinide plasma AUC 30 to 50% due to inhibition of CYP2C8.

Pyrazinamide: Pyrazinamide administration with favipiravir examined possible renal urate transporter interactions. Pyrazinamide increased blood uric acid levels 2 to 9 mg/dL over baseline. The addition of favipiravir increased blood uric acid levels 4 to 11 mg/dL over baseline, indicating a moderate additive effect. One subject developed headache and fever in association with elevated liver function tests (AST, ALT, gamma-glutamyl transferase, and lactate dehydrogenase) following pyrazinamide and favipiravir co-administration, which was determined to be a serious adverse event (SAE) and resolved upon discontinuation.

Adverse reactions from clinical trials and post-marketing experience in adult patients:

The following events have been identified as adverse reactions. The frequency category includes all reported events of moderate to severe intensity, regardless of the individual causality assessment. The adverse reactions are displayed by system organ class. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100) and rare (≥1/10,000 to <1/1000). 

3.5.2 Severity or grading of Adverse Events

68 11.1 Appendix 1 Figures referred to in the text

SPIRIT 2013 Statement: Defining Protocol Items for Clinical Trials

SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study

Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers

Modelling SARS-CoV-2 Dynamics: Implications for Therapy

Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load

Virological assessment of hospitalized patients with COVID-2019

Mutagenesis in Norovirus in Response to Favipiravir Treatment

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection

Experimental treatment with Favipiravir for COVID-19: an open-label control study

Favipiravir versus Arbidol for COVID-19: A Randomized Clinical

16 Cao 2020

Informed consent X 6 Randomisation X Demographics 7 X X 8 Medical history X X Concomitant medications X X X X XHIV status X X Urine Pregnancy test 9 X X Clinical assessment 10 X 

A comprehensive list of drug interactions and contraindications for Favipiravir and Lopinavir/ritonavir (Kaletra) can be found at the following link:https://liverpool-covid19.s3.eu-west-2.amazonaws.com/landingpage/Covid_InteractionSummary_Web_2020_Mar12.pdf

Kaletra contains lopinavir and ritonavir, both of which are inhibitors of the P450 isoform CYP3A. Kaletra should not be co-administered with medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life threatening events. These medicinal products include:

Concomitant medicinal product levels increased Anti-gout Colchicine Increased plasma concentrations of colchicine. Potential for serious and/or life-threatening reactions in patients with renal and/or hepatic impairment.

Astemizole, terfenadine Increased plasma concentrations of astemizole and terfenadine. Thereby, increasing the risk of serious arrhythmias from these agents.

Lurasidone Increased plasma concentrations of lurasidone which may increase the potential for serious and/or lifethreatening reactions.

Increased plasma concentrations of pimozide. Thereby, increasing the risk of serious haematologic abnormalities, or other serious adverse effects from this agent.